↓ Skip to main content

Cancer Epigenetics

Overview of attention for book
Cover of 'Cancer Epigenetics'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Cancer epigenetics: an introduction.
  3. Altmetric Badge
    Chapter 2 Community Resources and Technologies Developed Through the NIH Roadmap Epigenomics Program.
  4. Altmetric Badge
    Chapter 3 Epigenome-Wide Association Studies (EWAS): Past, Present, and Future
  5. Altmetric Badge
    Chapter 4 Epigenetic biomarkers in liver cancer.
  6. Altmetric Badge
    Chapter 5 Cancer type-specific epigenetic changes: gastric cancer.
  7. Altmetric Badge
    Chapter 6 Beyond the island: epigenetic biomarkers of colorectal and prostate cancer.
  8. Altmetric Badge
    Chapter 7 Prostate cancer epigenome.
  9. Altmetric Badge
    Chapter 8 CpG island hypermethylation as a biomarker for the early detection of lung cancer.
  10. Altmetric Badge
    Chapter 9 Analysis of DNA methylation in pancreatic cancer: an update.
  11. Altmetric Badge
    Chapter 10 Cancer Epigenetics
  12. Altmetric Badge
    Chapter 11 Epigenetics of prostate cancer.
  13. Altmetric Badge
    Chapter 12 Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options.
  14. Altmetric Badge
    Chapter 13 Techniques to access histone modifications and variants in cancer.
  15. Altmetric Badge
    Chapter 14 Single Base Resolution Analysis of 5-Methylcytosine and 5-Hydroxymethylcytosine by RRBS and TAB-RRBS
  16. Altmetric Badge
    Chapter 15 Quantitative DNA methylation analysis for epigenotyping of colorectal cancer.
  17. Altmetric Badge
    Chapter 16 Histone modifications associated with cancer cell migration and invasion.
  18. Altmetric Badge
    Chapter 17 Aberrant epigenetic modifications in radiation-resistant head and neck cancers.
  19. Altmetric Badge
    Chapter 18 Cancer-associated infectious agents and epigenetic regulation.
  20. Altmetric Badge
    Chapter 19 Toxicoepigenomics and cancer: implications for screening.
  21. Altmetric Badge
    Chapter 20 Human Papilloma Virus (HPV) Modulation of the HNSCC Epigenome.
  22. Altmetric Badge
    Chapter 21 Epigenetic Regulation of HIV, AIDS, and AIDS-Related Malignancies.
  23. Altmetric Badge
    Chapter 22 Epigenetics of colorectal cancer.
  24. Altmetric Badge
    Chapter 23 Epigenetics in breast and prostate cancer.
  25. Altmetric Badge
    Chapter 24 Epigenetic inhibitors.
  26. Altmetric Badge
    Chapter 25 Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies.
  27. Altmetric Badge
    Chapter 26 Epigenetic approaches in glioblastoma multiforme and their implication in screening and diagnosis.
  28. Altmetric Badge
    Chapter 27 Detection of Circulatory MicroRNAs in Prostate Cancer.
  29. Altmetric Badge
    Chapter 28 Identification and characterization of small-molecule inhibitors of lysine acetyltransferases.
  30. Altmetric Badge
    Chapter 29 Epigenetic regulation in biopsychosocial pathways.
  31. Altmetric Badge
    Chapter 30 Viral epigenetics.
  32. Altmetric Badge
    Chapter 31 P53 tumor suppression network in cancer epigenetics.
  33. Altmetric Badge
    Chapter 32 Promoter Hypermethylation as a Biomarker in Prostate Adenocarcinoma
  34. Altmetric Badge
    Chapter 33 Sequencing the cancer methylome.
  35. Altmetric Badge
    Chapter 34 Global DNA methylation profiling technologies and the ovarian cancer methylome.
  36. Altmetric Badge
    Chapter 35 Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer.
  37. Altmetric Badge
    Chapter 36 At the Crossroad Between Obesity and Gastric Cancer
  38. Altmetric Badge
    Chapter 37 Detection of epigenetic aberrations in the development of hepatocellular carcinoma.
  39. Altmetric Badge
    Chapter 38 Specific type epigenetic changes in cervical cancers.
  40. Altmetric Badge
    Chapter 39 Epigenetics in head and neck cancer.
  41. Altmetric Badge
    Chapter 40 Epigenetic therapy for colorectal cancer.
  42. Altmetric Badge
    Chapter 41 Epigenetics of gastric cancer.
Attention for Chapter 25: Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies.
Altmetric Badge

Mentioned by

1 tweeter


5 Dimensions

Readers on

15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies.
Chapter number 25
Book title
Cancer Epigenetics
Published in
Methods in molecular biology, January 2015
DOI 10.1007/978-1-4939-1804-1_25
Pubmed ID
Book ISBNs
978-1-4939-1803-4, 978-1-4939-1804-1

Aurore Claude-Taupin, Michael Boyer-Guittaut, Régis Delage-Mourroux, Eric Hervouet, Claude-Taupin, Aurore, Boyer-Guittaut, Michael, Delage-Mourroux, Régis, Hervouet, Eric


Breast cancer (BC) is one of the five most frequent cancers in the world. Despite earlier diagnosis and development of specific treatments, mortality has only declined of about 30 % during the past two decades. Two of the main reasons are the emergence of drug resistance and the absence of specific therapy for triple negative breast cancers (TNBC), which are characterized by a poor prognosis due to high proliferation rate. Therefore, the future goal of the fight against BC will be to find new therapeutic approaches to overcome drug resistances and cure TNBC. Recent research on gene expression profiles linked to the different types of BC cells have led to consider the use of epigenetic modulators to modulate the expression of genes deregulated in cancer. The preliminary encouraging results have demonstrated a positive effect of DNA Methyl Transferase (DNMT) and Histone DeAcetylase (HDAC) inhibitors on different types of BC, as well as drug-resistant cells, with low side effects. In this review, we will describe the different epigenetic modulators currently used or investigated in BC therapy research in vitro as well as preclinical and clinical trials, and promising compounds, which might be used in future BC therapies.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 27%
Researcher 3 20%
Student > Postgraduate 3 20%
Student > Master 1 7%
Other 1 7%
Other 2 13%
Unknown 1 7%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 40%
Agricultural and Biological Sciences 5 33%
Nursing and Health Professions 1 7%
Medicine and Dentistry 1 7%
Unknown 2 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2014.
All research outputs
of 4,553,834 outputs
Outputs from Methods in molecular biology
of 3,226 outputs
Outputs of similar age
of 145,274 outputs
Outputs of similar age from Methods in molecular biology
of 408 outputs
Altmetric has tracked 4,553,834 research outputs across all sources so far. This one is in the 3rd percentile – i.e., 3% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,226 research outputs from this source. They receive a mean Attention Score of 1.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 145,274 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 408 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.